Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Medical Genetics and Applied Genomics, |
RCV000086119 | SCV001446901 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000086119 | SCV001591336 | pathogenic | not provided | 2023-09-19 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Asn99 amino acid residue in BEST1. Other variant(s) that disrupt this residue have been observed in individuals with BEST1-related conditions (PMID: 21109774, 30718709), which suggests that this may be a clinically significant amino acid residue. Experimental studies have shown that this missense change affects BEST1 function (PMID: 11904445). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BEST1 protein function. ClinVar contains an entry for this variant (Variation ID: 99707). This missense change has been observed in individuals with vitelliform macular dystrophy (PMID: 10854112, 16612637; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 99 of the BEST1 protein (p.Asn99Lys). |
Retina International | RCV000086119 | SCV000118263 | not provided | not provided | no assertion provided | not provided |